The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The ubiquitin–proteasome system in cardiovascular diseases—a hypothesis extended
Abstract
During recent years, the ubiquitin-proteasome system has become known as the major pathway of non-lysosomal degradation of intracellular proteins, involving two sequential steps. In the first step, multiple moieties of ubiquitin are covalently bound to target proteins to be recognized and degraded by the multi-enzymatic proteasome complex in the second step. In addition to the elimination of damaged and unneeded proteins, this system fulfills an important function in the regulation of cellular mediators in various biological pathways. Foremost, these biological pathways include inflammation, cell proliferation, and apoptosis, all of which constitute important characteristics of atherosclerosis. Indeed, recent experimental evidence supports a potential involvement of the ubiquitin-proteasome system in the initiation, progression, and complication stage of atherogenesis. This review summarizes recent findings regarding the ubiquitin-proteasome system in cardiovascular diseases and discusses the potential use of proteasome inhibitors in cardiovascular therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidants, antioxidants, and the degenerative diseases of aging.
Ames, B. N., Shigenaga, M. K., & Hagen, T. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.7915 · Cited by 5,958
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839 · cited 1×
“This injurious stimulus seems to be aggravation of endogenous oxidative stress, leading to the oxidative modification of lipids, proteins, and DNA, and thereby to structural and functional alterations within the vascular wall [52,53].”
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Most likely, it is a combined effect, explaining the efficiacy of this class of drugs in a broad range of tumors, including solid and hematopoetic cancers and even those resistant to chemo- or radiotherapy [106,107].”
BackgroundDeng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C., Pickart, C., & Chen, Z. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00126-4 · Cited by 1,872
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y. (2002) · Nature · doi:10.1038/nature00767 · Cited by 751 · cited 1×
“Proteins that undergo ubiquitin-mediated degradation following phosphorylation or hydroxylation include the inhibitory molecules to nuclear factor kappa B (InB) and hypoxiainducible factor 1 alpha (HIF-1a), respectively [17,18].”
BackgroundNF-κB: pivotal mediator or innocent bystander in atherogenesis?
Collins, T., & Cybulsky, M. I. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10373 · Cited by 727 · cited 1×
“Under normal conditions NO is constitutively produced by endothelial cells, antagonizing pro-atherosclerotic processes in part by suppressing the transcriptional activity of NFnB, which has been identified as a pivotal mediator in the inflammatory-proliferative process of atherogenesis [55–60].”
BackgroundMDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641 · cited 1×
“MDM-2 facilitates transfer of p53 out of the nucleus and promotes the ubiquitination and degradation of p53 by the proteasome complex, leading to a reduction of the expression of negative cell cycle regulators such as cyclin-dependent kinase inhibitor p21 and pro-apoptotic mediators such as Bax [44,45].”
BackgroundMonoclonal T-cell proliferation and plaque instability in acute coronary syndromes.
Liuzzo, G., Goronzy, J. J., Yang, H., Kopecky, S. L., Holmes, D. R., Frye, R. L., & Weyand, C. M. (2000) · Circulation · doi:10.1161/01.cir.101.25.2883 · Cited by 552 · cited 1×
“It has to be noted, though, that up to 40% of all T cells in unstable plaques display the CD4+/CD28 phenotype, questioning the pathophysiological significance of the ubiquitin–proteasome system via the CD28-co-stimulatory route [89,91].”
BackgroundComparative resistance of the 20S and 26S proteasome to oxidative stress
REINHECKEL, T., SITTE, N., ULLRICH, O., KUCKELKORN, U., DAVIES, K. J. A., & GRUNE, T. (1998) · Biochemical Journal · doi:10.1042/bj3350637 · Cited by 447 · cited 1×
“In addition to the consideration of the 26S proteasome as being fairly sensitive to oxidative inactivation, there are a number of reports on the redox modulation of 20S proteasome proteolytic activity in vitro and in vivo, for instance by reaction with products of lipid peroxidation [70–72].”
Backgroundvon der Thüsen, J. H., van Vlijmen, B. J. M., Hoeben, R. C., Kockx, M. M., Havekes, L. M., van Berkel, T. J. C., & Biessen, E. A. L. (2002) · Circulation · doi:10.1161/01.cir.0000015502.97828.93 · Cited by 203
Rockwell, P., Yuan, H., Magnusson, R., & Figueiredo-Pereira, M. E. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1646 · Cited by 130 · cited 1×
“As a word of caution, it has to be mentioned that different cell populations can react differently to proteasome inhibition, and rather a pro-inflammatory and anti-apoptotic effect can be seen, for instance, in neuronal cells [110].”
Background
Cited by
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
“consensus sequence C-X2-CX[9-39]-C-X[1-3]-H-X[2-3]-C-X2-CX[4-48]-C-X2-C (where X means any amino acid).”
BackgroundJung, T., Catalgol, B., & Grune, T. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.001 · Cited by 389
Ubiquitin and Ubiquitin-Like Proteins in Protein Regulation
Herrmann, J., Lerman, L. O., & Lerman, A. (2007) · Circulation Research · doi:10.1161/01.res.0000264500.11888.f0 · Cited by 332
Self-citationProtein damage, repair and proteolysis
Chondrogianni, N., Petropoulos, I., Grimm, S., Georgila, K., Catalgol, B., Friguet, B., Grune, T., & Gonos, E. S. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.09.001 · Cited by 256
Khymenets, O., Fitó, M., Covas, M.-I., Farré, M., Pujadas, M.-A., Muñoz, D., Konstantinidou, V., & Torre, R. D. L. (2009) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2008.0079 · Cited by 68
Metadata
- Authors
- Herrmann, J.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01-01
- Volume
- 61
- Issue
- 1
- Pages
- 11-21
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2153876494
- Cited by
- 165
- References
- 11
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.